Issue 3/2012

  • Are released GM mosquitos safe?

    In this issue:

    • Novartis poised to enter HCV market with Enanta compound
    • Norway to use sequencing data in the country’s healthcare system
    • Oxford Nanopore shakes up Next-Gen sequencing market
    • BIO-Europe Spring: Antibodies – Unlocking new markets
    • Spain leads EU project for iPSCs in cell replacement therapies
    • Bioton joins forces with Actavis to develop biosimilar insulins
    • European Commission presents 2020 roadmap to bioeconomy

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/3/pos/1.html?sort=asc&cHash=2aa63e7a3c47f54d547eeaaa494e591b

Kurszettel

Alle Kurse

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD31.1%
  • THERAMETRICS (CH)0.05 CHF25.0%
  • FLAMEL TECHNOLOGIES (F)12.49 USD24.9%

FLOP

  • MOLOGEN (D)1.50 EUR-40.2%
  • ALLERGY THERAPEUTICS (UK)19.50 GBP-21.2%
  • SAREUM HOLDINGS (UK)0.64 GBP-21.0%

TOP

  • KARO BIO (S)28.70 SEK1693.8%
  • NICOX (F)11.57 EUR515.4%
  • SAREUM HOLDINGS (UK)0.64 GBP156.0%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 22.07.2016